Specific immunotherapy is the only treatment acting on the causes and not only on symptoms of respiratory allergy. It was first introduced as subcutaneous immunotherapy (SCIT) with the aim to induce immunological tolerance to the administered allergen(s). In the 1980s, sublingual immunotherapy (SLIT) was developed, mainly to improve the safety, which was a critical issue at that time. This article reviewed the available literature, including a large number of randomized controlled trials, meta-analyses, and real-life studies as well, on the outcomes of SCIT and SLIT concerning the treatment critical issues of the two routes, that are efficacy, safety, cost-effectiveness, and compliance to treatment. The efficacy of SCIT and SLIT is similar in respiratory allergy, providing, based on the induction of typical changes in the immunologic response, an early control of symptoms that steadily increases during the treatment and its efficacy lasts after the recommended duration of three years. Such results are the reason why SCIT and SLIT have economic advantage over symptomatic drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.23822/EurAnnACI.1764-1489.150 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical efficacy of sublingual immunotherapy for allergic rhinitis].
Nihon Yakurigaku Zasshi
January 2025
Department of Otolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University.
The prevalence of allergic rhinitis (AR) reached 49.2% in 2019. In particular, the prevalence of Japanese cedar (JC) pollinosis is 38.
View Article and Find Full Text PDFApplication of Nanoparticles for Immunotherapy of Allergic Rhinitis.
Int J Nanomedicine
November 2024
Laboratory Medicine Center, Allergy Center, Department of Transfusion Medicine, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, 310014, People's Republic of China.
Article Synopsis
- Allergen Immunotherapy (AIT) is currently the only treatment that targets the root cause of allergic rhinitis (AR), with established methods like subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) showing positive results but also side effects.
- Innovative approaches using nanoparticles (NPs), which are tiny particles (1-100 nm), are being explored as safer and more effective delivery systems for AIT, potentially enhancing immune modulation and drug concentration.
- The review discusses various types of nanoparticle delivery systems, such as chitosan, exosomes, metal, and viral nanoparticles, while highlighting their advantages and limitations, indicating that more research is needed to confirm their effectiveness in treating AR.
Efficacy of subcutaneous specific immunotherapy for allergic rhinitis combined with asthma: a retrospective analysis.
Am J Transl Res
October 2024
Department of Pulmonary and Critical Care Medicine, Renmin Hospital, Hubei University of Medicine Shiyan 442000, Hubei, China.
Objective: To evaluate the efficacy of subcutaneous specific immunotherapy (SCIT) for allergic rhinitis (AR) combined with asthma.
Methods: A retrospective analysis of clinical data from 93 patients with AR combined with asthma admitted to our hospital from January 2022 to January 2023 was conducted. Based on the treatment interventions received, the patients were divided into a control group (n=46, receiving sublingual specific immunotherapy [SLIT]) and an observation group (n=47, receiving SCIT).
Direct Comparison of Quality of Life in Patients with Allergic Rhinitis Undergoing Sublingual Versus Subcutaneous Immunotherapy.
J Clin Med
October 2024
Department of Otolaryngology/Head and Neck Surgery, University of North Carolina, Chapel Hill, NC 27599, USA.
: Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are commonly used for allergic rhinitis (AR), yet limited research has directly compared their effects on quality of life (QoL). We aimed to assess QoL differences between SLIT and SCIT recipients. As both forms of immunotherapy have reported benefits, we hypothesize that patients undergoing SLIT and SCIT will have comparable QoL improvements.
View Article and Find Full Text PDFProbiotics as adjuvants to mitigate adverse reactions and enhance effectiveness in Food Allergy Immunotherapy.
Scand J Immunol
December 2024
Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Article Synopsis
- Food allergies have risen significantly in young children, impacting quality of life and healthcare costs, leading to a focus on Food Allergy Allergen Immunotherapy (FA-AIT) as a treatment option.
- FA-AIT methods, including SCIT, EPIT, OIT, and SLIT, involve gradual exposure to allergens to build tolerance, but they can also cause adverse reactions.
- Recent research highlights the potential of gut microbiota and specific probiotics as adjuvants to improve the safety and effectiveness of AIT, emphasizing the need for more clinical studies to validate these approaches.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!